Disease · MONDO_0013792
Comparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 33
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Any Serious Adverse Event Within the 90-day Study Period | 100 of 500 | 128 of 500 | 1,000 | NCT01176565 | Trial comparisons |
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Hypotension Within 72 Hours | 3 of 500 | 6 of 500 | 1,000 | NCT01176565 | Trial comparisons |
Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Neurological Deterioration Within 24 Hours, Defined by a Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score From Baseline, Not Related to Sedation or Hypnotic-agent Use and Sustained for at Least 8 Hours. | 40 of 500 | 55 of 500 | 1,000 | NCT01176565 | Trial comparisons |
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Treatment-related Serious Adverse Event Within 72 Hours of Randomization | 6 of 500 | 8 of 500 | 1,000 | NCT01176565 | Trial comparisons |
| Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: serious adverse events | 100 of 500 | 128 of 500 | 1,000 | NCT01176565 | Trial comparisons |
Standard SBP Reduction Arm vs Intensive SBP Reduction Arm: Hematoma Expansion (Number of Patients With Hematoma Expansion of 33% or Greater Between the Baseline and 24 +/- 6 Hours Head CTs, as Measured by the Central Reader for Patients With Readable Scans for Both Time Points Submitted by Data Lock.) | 104 of 426 | 85 of 450 | 876 | NCT01176565 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Number of Subjects With Serious Adverse Events Within 7 Days | 24 of 144 | 26 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Number of Patients With Symptomatic Cerebral Edema | 9 of 144 | 5 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Number of Subjects Experiencing Serious Adverse Events | 39 of 144 | 49 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Adverse Event of Special Interest: Number of Patients With New Visual or Auditory Changes | 3 of 144 | 4 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Adverse Event of Special Interest: Number of Patients With Allergic Reactions (During Infusion of Study Drug) | 3 of 144 | 0 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Adverse Event of Special Interest: Number of Patients With Hypotension | 1 of 144 | 2 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: deaths from any cause | 12 of 144 | 12 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: serious adverse events | 39 of 144 | 50 of 147 | 291 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days | 48 of 140 | 47 of 143 | 283 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Proportion of Patients With mRS Score 0-3 at 90 Days | 91 of 140 | 82 of 143 | 283 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 180 Days | 61 of 135 | 48 of 135 | 270 | NCT02175225 | Trial comparisons |
| Deferoxamine Mesylate vs Normal Saline: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-3 at 180 Days | 97 of 135 | 92 of 135 | 270 | NCT02175225 | Trial comparisons |
| Acetaminophen vs Bromocriptine and Acetaminophen: deaths from any cause | 0 of 21 | 1 of 26 | 47 | NCT03496545 | Trial comparisons |
| Acetaminophen vs Bromocriptine and Acetaminophen: serious adverse events | 0 of 21 | 1 of 26 | 47 | NCT03496545 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0013792/comparisons